newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology's Retina Subspecialty Meeting, RET13 - Se